Prosecution Insights
Last updated: November 04, 2026
Application No. 18/928,970

INDIVIDUALIZED SOLID DOSAGE PRODUCTS AND A SYSTEM AND METHOD FOR THE GLOBALLY INTEGRATED PHARMACEUTICAL MANUFACTURING AND ITS MONITORING THEREOF

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Oct 28, 2024
Priority
Apr 13, 2015 — provisional 62/178,476 +2 more
Examiner
FARRAR, LAUREN PENG
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Pharmacoustics Technologies LLC
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
3y 12m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
625 granted / 795 resolved
+8.6% vs TC avg
Strong +16% interview lift
Without
With
+15.8%
Interview Lift
resolved cases with interview
Typical timeline
6y 0m
Avg Prosecution
47 currently pending
Career history
837
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
56.8%
+16.8% vs TC avg
§102
22.4%
-17.6% vs TC avg
§112
12.3%
-27.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 795 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 13 and all dependents thereof are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 13 recites the limitation "the step of sealing" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 4-11, 13-14 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kraft (US 2012/0041778 A1). With regard to claim 1, Kraft discloses A solid dosage product (Fig. 4a) having a tailored dissolution profile, the solid dosage product comprising: a) a carrier block (shown in Fig. 4a as stage 3) defining a plurality of compartments (400, 410, and 420), each respective compartment configured to receive one or more active pharmaceutical ingredients (drug 1, drug 2, drug 3 of Fig. 4a), the carrier block being digestible within an animal such that each respective active pharmaceutical ingredient is controllably released ([0136]); and b) one or more coating layers applied to the carrier block ([0079]-[0081]). With regard to claim 4, Kraft discloses wherein a respective active pharmaceutical ingredient comprises an active ingredient encapsulated by one or more excipients (see Fig. 4a, each pharmaceutical is encapsulated by an excipient creating the contained drug compartments). With regard to claim 5, Kraft discloses wherein the active ingredient comprises about 75 percent of the respective active pharmaceutical ingredient (Drug 1 is shown as being about 75 percent of the active ingredient (shown in fig. 4a as being the base of the capsule, with drug 2 and 3 be added on as smaller layers). With regard to claim 6, Kraft discloses wherein solid dosage product further includes one or more excipients ([0079]-[0081], different coating layers can be considered the excipients), wherein the one or more excipients is contained within one or more of the carrier block, the one or more compartments or the one or more coating layers ([0079]-[0081]). With regard to claim 7, Kraft discloses wherein the one or more pharmaceutical ingredients is selected from the list consisting of a pellet, a powder, a liquid, an emulsion and a gel ([0079]). With regard to claim 8, Kraft discloses wherein the carrier block is fabricated by additive manufacturing using digestible print materials (this a product by process claim and the prior art must only teach the recited structures)(Fig. 4a shows an additive process in which a capsule containing dug 1 is then moved to stage 2 which adds a layer containing drug 2 and then moved to stage 3 which adds a layer container drug 3). With regard to claim 9, Kraft discloses wherein a respective pharmaceutical ingredient is selected from the list consisting drugs, proteins, peptides, small molecules, nutritional supplements, vaccines and gene therapies ([0079]). With regard to claim 10, Kraft discloses further comprising a solid dosage body (one of the coating layers of [0079]-[0081], can be considered a solid dosage body), wherein the carrier block is incorporated within a portion of the solid dosage body. With regard to claim 11, Kraft discloses A method for manufacturing a solid dosage product having a tailored dissolution profile, the method comprising: a) manufacturing a digestible carrier block (Fig. 3 and 3), the carrier block defining a plurality of compartments (each carrier block 330 holds multipe different medications in different layers of the carrier block), each respective compartment configured to receive an active pharmaceutical ingredient (as shown as Fig. 4); b) filling a respective compartment with one or more respective active pharmaceutical ingredients (see Fig. 4, drug 1, drug 2, drug 3); and c) coating the carrier block with one or more coating layers ([0079], [0080]). With regard to claim 13, Kraft discloses further comprising a step of sealing the carrier block with one or more digestible top layers (340, [0083]) after filling the compartments and before coating the carrier block ([0083], [0088]). With regard to claim 14, Kraft discloses wherein the steps of manufacturing, filling and coating utilize dedicated filler heads at each step for each material being manufactured, filled or coated (see each of 310a, 310b, and 310 as well as the next two stages that are separate including 340 and 350, all shown in Fig. 3). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 2-3 and 12 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kraft (US 2012/0041778 A1) in view of Johnson et al. (US 2016/0345906 A1). With regard to claim 2, Kraft discloses the claimed invention except for an electronic device. Johnson teaches an ingestible capsule that maybe also include an electronic device within a compartment ([0004]). Therefore, it would be prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Kraft with the electronic device as taught by Johnson for the purpose of providing additional information about the capsule while the device is within the body ([0004]). With regard to claim 3, Kraft discloses the claimed invention except for an electronic device. Johnson teaches wherein the one or more electronic devices is selected from the list consisting of a wireless transmitter, a remotely activated device, a logging device and a patient bonding device ([0004], sensor or recorder could be considered a logging device). Therefore, it would be prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Kraft with the electronic device as taught by Johnson for the purpose of providing additional information about the capsule while the device is within the body ([0004]). With regard to claim 12, Kraft disclose the claimed invention except for the electronic devices. Johnson teaches an ingestible capsule that maybe also include an electronic device within a compartment ([0004]). Therefore, it would be prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Kraft with the electronic device as taught by Johnson for the purpose of providing additional information about the capsule while the device is within the body ([0004]). Claim(s) 15-18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kraft (US 2012/0041778 A1) in view of Islam (US 2014/0183362). With regard to claim 15, Kraft discloses a respective filler head responsible for manufacture of the carrier block, the carrier block, a respective filler head responsible for filling of each respective compartment, the active pharmaceutical ingredient, a respective filler head responsible for each coating layer, and each of the one or more coating layers (Fig. 3, heads 310a, 310b, 310c, 340 and 350). However, Kraft does not disclose Process Analytical Technology systems. Islam teaches the methods step of monitoring using Process Analytical Technology systems ([006]). Therefore, it would be prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Kraft with the Process Analytical Technology as taught by Islam for the purpose of controlling manufacturing through timely evaluations to assess for quality and performance ([0063]). With regard to claim 16, Kraft discloses the claimed invention except for the specific sensors. Islam teaches wherein the Process Analytical Technology systems include one or more sensors configured to perform one or more of: Raman spectroscopy; X-ray; nuclear magnetic resonance (NMR); terahertz pulsed imaging; laser induced breakdown spectroscopy ([0063]); acoustic emission (AE); air-coupled acoustic testing; contact ultrasonic testing; photo-acoustics testing including thermomechanical excitation and/or piezoelectric sensing; near infrared (NIR) ([0063]); and micro-thermal probing. Therefore, it would be prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Kraft with the Process Analytical Technology as taught by Islam for the purpose of controlling manufacturing through timely evaluations to assess for quality and performance ([0063]). With regard to claim 17, Kraft discloses further comprising the steps of: d) manufacturing a calibration model block, the calibration model block being used to establish requirements for an acceptable final dosage form ([0086]); e) comparing the digestible carrier block with the calibration model block during manufacture of the digestible carrier block ([0086], [0067]); and f) if needed, modifying the manufacturing of the digestible carrier block so that the manufactured digestible carrier block meets the requirements for an acceptable final dosage form ([0086], [0067]). However, Kraft does not disclose Process Analytical Technology systems. Islam teaches the methods step of monitoring using Process Analytical Technology systems ([006]). Therefore, it would be prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the device of Kraft with the Process Analytical Technology as taught by Islam for the purpose of controlling manufacturing through timely evaluations to assess for quality and performance ([0063]). With regard to claim 18, Kraft discloses wherein the step of comparing includes use of one or more of: cluster analysis, supervised machine learning, a neural network ([0068]), genetic algorithms, principal component analysis, decision trees ([0016]) and Bayesian statistics. Double Patenting Claims 1-10 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 12,128,135 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because claim 1of the present invention is a broader version of claim 1 of U.S. Patent No. 12,128,135 B2. Therefore, claim 1 of U.S. Patent No. 12,128,135 B2 teaches all the limitations of claim 1 of the present invention including a solid dosage product having a carrier block with a plurality of compartments and one or more coating layers. Further the dependent claims of the present invention are taught by the dependent claims of U.S. Patent No. 12,128,135 B2 as outlined below: Present Invention U.S. Patent No. 12,128,135 B2 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 9 10 10 Claims 11 and all dependent claims thereof are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 10,653,622 B1. Although the claims at issue are not identical, they are not patentably distinct from each other because claim 1of the present invention is a broader version of claim 1 of U.S. Patent No. 10,653,622 B1. Therefore, claim 1 of U.S. Patent No. 10,653,622 B1 teaches all the limitations of claim 1 of the present invention including the method of manufacturing a digestible carrier block, filling the compartments and coating the carrier block. Further the dependent claims of the present invention are taught by the dependent claims of U.S. Patent No. 10,653,622 B1 as outlined below: Present Invention U.S. Patent No. 10,653,622 B1 14 1 15 1 16 3 Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN P FARRAR whose telephone number is (571)270-1496. The examiner can normally be reached Monday - Friday 9am - 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin Sirmons can be reached on 571-272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Lauren P Farrar/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Oct 28, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779110
SYSTEMS, DEVICES AND METHODS FOR SUSTAINED DELIVERY OF A THERAPEUTIC FLUID
5y 0m to grant Granted Nov 03, 2026
Patent 12779130
A DRIVE MECHANISM FOR AN APPLICATOR FOR DELIVERING A DOSE OF MEDICAMENT AND A CORRESPONDING APPLICATOR
3y 10m to grant Granted Nov 03, 2026
Patent 12779194
ELECTRODE ASSEMBLIES OF A BASKET CATHETER HAVING MECHANICAL RETAINERS AND METHODS OF THE SAME
3y 10m to grant Granted Nov 03, 2026
Patent 12779119
SYSTEM FOR REMOTE DRUG MONITORING AND TITRATION
3y 0m to grant Granted Nov 03, 2026
Patent 12773543
APPARATUSES AND METHODS FOR DELIVERING POWDERED AGENTS
3y 2m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
94%
With Interview (+15.8%)
6y 0m (~3y 12m remaining)
Median Time to Grant
Low
PTA Risk
Based on 795 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month